Insider trading activities (stock purchases, sales, and option exercises)
reported by insiders of Warner Chilcott Ltd (WCRX)
since 2010 are shown in Table 1 and Table 2.
Table 1 shows the monthly insider trading data of Warner Chilcott Ltd.
Table 2 shows the detailed insider transactions.
This company's CIK number is 1323854.
Total stock buying since 2010: $0.
Total stock sales since 2010: $3,846,562,839.
Total stock option exercises since 2010: $320,756.
Table 3. Detailed insider trading at Warner Chilcott Ltd (WCRX)
| Trade Date |
Insider Name |
Trade Type |
Shares |
Price ($) |
Value ($) |
| 2013-07-01 | Sullivan Ryan T (VP, General Counsel & Secr.) | Sale | 169 | 19.88 | 3,359 |
| 2013-07-01 | Halstead Michael (Senior V.P., Corp. Development) | Sale | 366 | 19.88 | 7,276 |
| 2013-04-01 | Van Zoonen Marinus Johannes (President, Europe/Int'l & Mkt.) | Sale | 703 | 13.41 | 9,427 |
| 2013-03-04 | Connaughton John (Director) | Sale | 10,590,608 | 13.47 | 142,655,489 |
| 2013-03-01 | Ellman Herman (Senior V.P., Clinical Devel.) | Sale | 1,666 | 13.38 | 22,292 |
| 2013-02-28 | Rodriguez Rama Francisco (Senior V.P., Tech. Operations) | Sale | 820 | 13.46 | 11,040 |
| 2013-02-28 | Fenton Andrew (Senior V.P., CIO) | Sale | 1,390 | 13.46 | 18,714 |
| 2013-02-28 | Halstead Michael (Senior V.P., Corp. Development) | Sale | 1,747 | 13.46 | 23,521 |
| 2013-02-28 | Fuhrmann Rochelle (Senior V.P., Finance) | Sale | 1,728 | 13.46 | 23,265 |
| 2013-02-28 | Gilligan Claire A (Senior V.P., Quality) | Sale | 2,354 | 13.46 | 31,694 |
| 2013-02-28 | Van Zoonen Marinus Johannes (President, Europe/Int'l & Mkt.) | Sale | 15,869 | 13.46 | 213,660 |
| 2013-02-28 | Boissonneault Roger M (CEO & President) | Sale | 18,730 | 13.46 | 252,180 |
| 2013-02-28 | Cross Leland H (Senior V.P., Tech. Operations) | Sale | 1,324 | 13.46 | 17,826 |
| 2013-02-28 | Howard Alvin D (Sr. V.P., Regulatory Affairs) | Sale | 1,728 | 13.46 | 23,265 |
| 2013-02-27 | Van Zoonen Marinus Johannes (President, Europe/Int'l & Mkt.) | Option Ex | 31,737 | .00 | 0 |
| 2013-02-19 | Fenton Andrew (Senior V.P., CIO) | Sale | 419 | 14.53 | 6,087 |
| 2013-02-19 | Halstead Michael (Senior V.P., Corp. Development) | Sale | 419 | 14.53 | 6,087 |
| 2013-02-19 | Fuhrmann Rochelle (Senior V.P., Finance) | Sale | 767 | 14.53 | 11,142 |
| 2013-02-19 | Gilligan Claire A (Senior V.P., Quality) | Sale | 1,045 | 14.53 | 15,181 |
| 2013-02-19 | Van Zoonen Marinus Johannes (President, Europe/Int'l & Mkt.) | Sale | 2,562 | 14.53 | 37,220 |
| 2013-02-19 | Boissonneault Roger M (CEO & President) | Sale | 7,928 | 14.53 | 115,177 |
| 2013-02-19 | Cross Leland H (Senior V.P., Tech. Operations) | Sale | 553 | 14.53 | 8,033 |
| 2013-02-19 | Ellman Herman (Senior V.P., Clinical Devel.) | Sale | 691 | 14.53 | 10,038 |
| 2013-02-19 | Herendeen Paul (Exec. V.P. and CFO) | Sale | 1,969 | 14.53 | 28,605 |
| 2013-02-19 | Howard Alvin D (Sr. V.P., Regulatory Affairs) | Sale | 767 | 14.53 | 11,142 |
| 2013-02-01 | Fenton Andrew (Senior V.P., CIO) | Sale | 996 | 14.18 | 14,121 |
| 2013-02-01 | Halstead Michael (Senior V.P., Corp. Development) | Sale | 998 | 14.18 | 14,149 |
| 2013-02-01 | Fuhrmann Rochelle (Senior V.P., Finance) | Sale | 998 | 14.18 | 14,149 |
| 2013-02-01 | Gilligan Claire A (Senior V.P., Quality) | Sale | 1,377 | 14.18 | 19,523 |
| 2013-02-01 | Van Zoonen Marinus Johannes (President, Europe/Int'l & Mkt.) | Sale | 13,790 | 14.18 | 195,514 |
| 2013-02-01 | Boissonneault Roger M (CEO & President) | Sale | 9,125 | 14.18 | 129,374 |
| 2013-02-01 | Cross Leland H (Senior V.P., Tech. Operations) | Sale | 808 | 14.18 | 11,455 |
| 2013-02-01 | Ellman Herman (Senior V.P., Clinical Devel.) | Sale | 1,010 | 14.18 | 14,319 |
| 2013-02-01 | Herendeen Paul (Exec. V.P. and CFO) | Sale | 2,840 | 14.18 | 40,265 |
| 2013-02-01 | Howard Alvin D (Sr. V.P., Regulatory Affairs) | Sale | 1,010 | 14.18 | 14,319 |
| 2013-01-30 | Fenton Andrew (Senior V.P., CIO) | Sale | 351 | 13.38 | 4,697 |
| 2013-01-30 | Halstead Michael (Senior V.P., Corp. Development) | Sale | 320 | 13.38 | 4,282 |
| 2013-01-30 | Fuhrmann Rochelle (Senior V.P., Finance) | Sale | 282 | 13.38 | 3,774 |
| 2013-01-30 | Gilligan Claire A (Senior V.P., Quality) | Sale | 489 | 13.38 | 6,544 |
| 2013-01-30 | Van Zoonen Marinus Johannes (President, Europe/Int'l & Mkt.) | Sale | 2,215 | 13.90 | 30,792 |
| 2013-01-30 | Boissonneault Roger M (CEO & President) | Sale | 8,470 | 13.38 | 113,362 |
| 2013-01-30 | Cross Leland H (Senior V.P., Tech. Operations) | Sale | 465 | 13.38 | 6,223 |
| 2013-01-30 | Ellman Herman (Senior V.P., Clinical Devel.) | Sale | 586 | 13.38 | 7,843 |
| 2013-01-30 | Herendeen Paul (Exec. V.P. and CFO) | Sale | 2,208 | 13.38 | 29,551 |
| 2013-01-30 | Howard Alvin D (Sr. V.P., Regulatory Affairs) | Sale | 591 | 13.38 | 7,909 |
| 2013-01-22 | Fenton Andrew (Senior V.P., CIO) | Sale | 621 | 13.50 | 8,383 |
| 2013-01-22 | Halstead Michael (Senior V.P., Corp. Development) | Sale | 488 | 13.50 | 6,588 |
| 2013-01-22 | Fuhrmann Rochelle (Senior V.P., Finance) | Sale | 488 | 13.50 | 6,588 |
| 2013-01-22 | Gilligan Claire A (Senior V.P., Quality) | Sale | 949 | 13.50 | 12,811 |
| 2013-01-22 | Boissonneault Roger M (CEO & President) | Sale | 13,924 | 13.50 | 187,974 |
| 2013-01-22 | Cross Leland H (Senior V.P., Tech. Operations) | Sale | 839 | 13.50 | 11,326 |
| 2013-01-22 | Ellman Herman (Senior V.P., Clinical Devel.) | Sale | 1,166 | 13.50 | 15,741 |
| 2013-01-22 | Herendeen Paul (Exec. V.P. and CFO) | Sale | 4,305 | 13.50 | 58,117 |
| 2013-01-22 | Howard Alvin D (Sr. V.P., Regulatory Affairs) | Sale | 1,222 | 13.50 | 16,497 |
| 2012-11-28 | Murray Stephen P | Sale | 6,491,618 | 11.41 | 74,069,361 |
| 2012-11-20 | Murray Stephen P | Sale | 5,000,000 | 11.66 | 58,300,000 |
| 2012-10-01 | Halstead Michael (Senior V.P., Corp. Development) | Sale | 77 | 13.55 | 1,043 |
| 2012-10-01 | Gilligan Claire A (Senior V.P., Quality) | Sale | 264 | 13.55 | 3,577 |
| 2012-09-11 | Bain Capital (wc) Netherlands B.v (10% Owner) | Sale | 12,890,449 | 13.10 | 168,864,881 |
| 2012-09-11 | J.p. Morgan Partners Global Investors (cayman/selldown) Iii, L.p. | Sale | 28,762,425 | 13.10 | 376,787,767 |
| 2012-09-11 | Ellman Herman (Senior V.P., Clinical Devel.) | Sale | 23,500 | 13.10 | 307,850 |
| 2012-09-11 | Hara Izumi (Senior V.P.) | Sale | 126,993 | 13.10 | 1,663,608 |
| 2012-09-11 | Herendeen Paul (Exec. V.P. and CFO) | Sale | 309,240 | 13.10 | 4,051,044 |
| 2012-09-11 | Howard Alvin D (Sr. V.P., Regulatory Affairs) | Sale | 147,639 | 13.10 | 1,934,070 |
| 2012-09-11 | Murray Stephen P | Sale | 14,000,000 | 13.10 | 183,400,000 |
| 2012-09-11 | Jpmp Capital Corp | Sale | 28,762,425 | 13.10 | 376,787,767 |
| 2012-09-11 | Abbrecht Todd M | Sale | 14,000,000 | 13.10 | 183,400,000 |
| 2012-09-11 | Thomas H Lee Advisors Alternative V Ltd Ldc | Sale | 14,000,000 | 13.10 | 183,400,000 |
| 2012-09-11 | Connaughton John (Director) | Sale | 12,890,449 | 13.10 | 168,864,881 |
| 2012-07-02 | Halstead Michael (Senior V.P., Corp. Development) | Sale | 355 | 17.96 | 6,375 |
| 2012-04-02 | Van Zoonen Marinus Johannes (President, Europe/Int'l & Mkt.) | Sale | 703 | 16.95 | 11,915 |
| 2012-03-01 | Fenton Andrew (Senior V.P., CIO) | Sale | 386 | 17.00 | 6,561 |
| 2012-03-01 | Halstead Michael (Senior V.P., Corp. Development) | Sale | 725 | 17.00 | 12,324 |
| 2012-03-01 | Fuhrmann Rochelle (Senior V.P., Finance) | Sale | 710 | 17.00 | 12,069 |
| 2012-03-01 | Gilligan Claire A (Senior V.P., Quality) | Sale | 973 | 17.00 | 16,540 |
| 2012-03-01 | Van Zoonen Marinus Johannes (President, Europe/Int'l & Mkt.) | Sale | 2,485 | 17.00 | 42,242 |
| 2012-03-01 | Boissonneault Roger M (CEO & President) | Sale | 5,320 | 17.00 | 90,434 |
| 2012-03-01 | Cross Leland H (Senior V.P., Tech. Operations) | Sale | 558 | 17.00 | 9,485 |
| 2012-03-01 | Hara Izumi (Sr. VP, Gen. Counsel & Sec.) | Sale | 710 | 17.00 | 12,069 |
| 2012-03-01 | Herendeen Paul (Exec. V.P. and CFO) | Sale | 1,827 | 17.00 | 31,057 |
| 2012-03-01 | Howard Alvin D (Sr. V.P., Regulatory Affairs) | Sale | 710 | 17.00 | 12,069 |
| 2012-02-29 | Van Zoonen Marinus Johannes (President, Europe/Int'l & Mkt.) | Option Ex | 4,970 | .00 | 0 |
| 2012-02-21 | Fenton Andrew (Senior V.P., CIO) | Sale | 409 | 16.82 | 6,880 |
| 2012-02-21 | Halstead Michael (Senior V.P., Corp. Development) | Sale | 409 | 16.82 | 6,880 |
| 2012-02-21 | Fuhrmann Rochelle (Senior V.P., Finance) | Sale | 752 | 16.82 | 12,650 |
| 2012-02-21 | Gilligan Claire A (Senior V.P., Quality) | Sale | 1,030 | 16.82 | 17,327 |
| 2012-02-21 | Van Zoonen Marinus Johannes (President, Europe/Int'l & Mkt.) | Sale | 2,561 | 16.82 | 43,083 |
| 2012-02-21 | Boissonneault Roger M (CEO & President) | Sale | 5,628 | 16.82 | 94,679 |
| 2012-02-21 | Cross Leland H (Senior V.P., Tech. Operations) | Sale | 590 | 16.82 | 9,925 |
| 2012-02-21 | Ellman Herman (Senior V.P., Clinical Devel.) | Sale | 677 | 16.82 | 11,389 |
| 2012-02-21 | Hara Izumi (Sr. VP, Gen. Counsel & Sec.) | Sale | 752 | 16.82 | 12,650 |
| 2012-02-21 | Herendeen Paul (Exec. V.P. and CFO) | Sale | 1,933 | 16.82 | 32,518 |
| 2012-02-21 | Howard Alvin D (Sr. V.P., Regulatory Affairs) | Sale | 752 | 16.82 | 12,650 |
| 2012-01-30 | Fenton Andrew (Senior V.P., CIO) | Sale | 351 | 16.45 | 5,774 |
| 2012-01-30 | Halstead Michael (Senior V.P., Corp. Development) | Sale | 320 | 16.45 | 5,264 |
| 2012-01-30 | Fuhrmann Rochelle (Senior V.P., Finance) | Sale | 281 | 16.45 | 4,623 |
| 2012-01-30 | Gilligan Claire A (Senior V.P., Quality) | Sale | 480 | 16.45 | 7,896 |
| 2012-01-30 | Van Zoonen Marinus Johannes (President, Europe/Int'l & Mkt.) | Sale | 2,215 | 16.45 | 36,441 |
| 2012-01-30 | Boissonneault Roger M (CEO & President) | Sale | 8,317 | 16.45 | 136,831 |
| 2012-01-30 | Cross Leland H (Senior V.P., Tech. Operations) | Sale | 504 | 16.45 | 8,291 |
| 2012-01-30 | Ellman Herman (Senior V.P., Clinical Devel.) | Sale | 579 | 16.45 | 9,525 |
| 2012-01-30 | Hara Izumi (Sr. VP, Gen. Counsel & Sec.) | Sale | 635 | 16.45 | 10,447 |
| 2012-01-30 | Herendeen Paul (Exec. V.P. and CFO) | Sale | 2,187 | 16.45 | 35,980 |
| 2012-01-30 | Howard Alvin D (Sr. V.P., Regulatory Affairs) | Sale | 579 | 16.45 | 9,525 |
| 2012-01-23 | Fenton Andrew (Senior V.P., CIO) | Sale | 621 | 17.32 | 10,755 |
| 2012-01-23 | Halstead Michael (Senior V.P., Corp. Development) | Sale | 487 | 17.32 | 8,434 |
| 2012-01-23 | Fuhrmann Rochelle (Senior V.P., Finance) | Sale | 487 | 17.32 | 8,434 |
| 2012-01-23 | Gilligan Claire A (Senior V.P., Quality) | Sale | 933 | 17.32 | 16,159 |
| 2012-01-23 | Boissonneault Roger M (CEO & President) | Sale | 13,652 | 17.32 | 236,452 |
| 2012-01-23 | Cross Leland H (Senior V.P., Tech. Operations) | Sale | 921 | 17.32 | 15,951 |
| 2012-01-23 | Ellman Herman (Senior V.P., Clinical Devel.) | Sale | 1,169 | 17.32 | 20,247 |
| 2012-01-23 | Hara Izumi (Sr. VP, Gen. Counsel & Sec.) | Sale | 1,169 | 17.32 | 20,247 |
| 2012-01-23 | Herendeen Paul (Exec. V.P. and CFO) | Sale | 4,149 | 17.32 | 71,860 |
| 2012-01-23 | Howard Alvin D (Sr. V.P., Regulatory Affairs) | Sale | 1,225 | 17.32 | 21,217 |
| 2012-01-11 | Fenton Andrew (Senior V.P., CIO) | Sale | 558 | 16.66 | 9,296 |
| 2012-01-11 | Halstead Michael (Senior V.P., Corp. Development) | Sale | 452 | 16.66 | 7,530 |
| 2012-01-11 | Fuhrmann Rochelle (Senior V.P., Finance) | Sale | 411 | 16.66 | 6,847 |
| 2012-01-11 | Gilligan Claire A (Senior V.P., Quality) | Sale | 839 | 16.66 | 13,977 |
| 2012-01-11 | Cross Leland H (Senior V.P., Tech. Operations) | Sale | 908 | 16.66 | 15,127 |
| 2012-01-11 | Ellman Herman (Senior V.P., Clinical Devel.) | Sale | 1,042 | 16.66 | 17,359 |
| 2012-01-11 | Hara Izumi (Sr. VP, Gen. Counsel & Sec.) | Sale | 1,095 | 16.66 | 18,242 |
| 2012-01-11 | Howard Alvin D (Sr. V.P., Regulatory Affairs) | Sale | 1,146 | 16.66 | 19,092 |
| 2011-10-21 | Fawzi Mahdi B (President, Research & Develop.) | Sale | 2,418 | 16.80 | 40,622 |
| 2011-10-03 | Halstead Michael (Senior V.P., Corp. Development) | Sale | 78 | 14.03 | 1,094 |
| 2011-10-03 | Gilligan Claire A (Senior V.P., Quality) | Sale | 270 | 14.03 | 3,788 |
| 2011-06-10 | Cross Leland H (Senior V.P., Tech. Operations) | Sale | 79,563 | 22.29 | 1,773,777 |
| 2011-06-09 | Cross Leland H (Senior V.P., Tech. Operations) | Sale | 100,000 | 22.41 | 2,241,000 |
| 2011-04-01 | Van Zoonen Marinus Johannes (Pres., Europe/Int'l&Glob. Mkt.) | Sale | 703 | 23.30 | 16,379 |
| 2011-03-30 | Bain Capital (wc) Netherlands B.v (10% Owner) | Sale | 446,196 | 22.44 | 10,010,853 |
| 2011-03-30 | Gilligan Claire A (Senior V.P. Global Quality) | Sale | 1,543 | 23.25 | 35,874 |
| 2011-03-30 | J.p. Morgan Partners Global Investors (cayman/selldown) Iii, L.p. (10% Owner) | Sale | 932,389 | 22.44 | 20,919,079 |
| 2011-03-30 | Bruno Anthony D (Exec. V.P., Corp. Development) | Sale | 16,848 | 23.25 | 391,716 |
| 2011-03-30 | Ellman Herman (Senior V.P., Clinical Devel.) | Sale | 3,546 | 23.25 | 82,444 |
| 2011-03-30 | Hara Izumi (Sr. VP, Gen. Counsel & Sec.) | Sale | 3,713 | 23.25 | 86,327 |
| 2011-03-30 | Herendeen Paul (Exec. V.P. and CFO) | Sale | 15,406 | 23.25 | 358,189 |
| 2011-03-30 | Reichel Carl W (President, Pharmaceuticals) | Sale | 18,020 | 23.25 | 418,965 |
| 2011-03-30 | Murray Stephen P (Director) | Sale | 466,194 | 22.44 | 10,459,528 |
| 2011-03-30 | Jpmp Capital Corp (10% Owner) | Sale | 932,389 | 22.44 | 20,919,079 |
| 2011-03-30 | Abbrecht Todd M | Sale | 466,194 | 22.44 | 10,461,393 |
| 2011-03-30 | Connaughton John (Director) | Sale | 446,196 | 22.44 | 10,010,853 |
| 2011-03-16 | Bain Capital (wc) Netherlands B.v (10% Owner) | Sale | 6,919,748 | 22.44 | 155,251,466 |
| 2011-03-16 | Gilligan Claire A (Senior V.P. Global Quality) | Sale | 26,411 | 23.25 | 614,055 |
| 2011-03-16 | J.p. Morgan Partners Global Investors (cayman/selldown) Iii, L.p. (10% Owner) | Sale | 15,722,194 | 22.44 | 352,743,144 |
| 2011-03-16 | Bruno Anthony D (Exec. V.P., Corp. Development) | Sale | 400,000 | 23.25 | 9,300,000 |
| 2011-03-16 | Ellman Herman (Senior V.P., Clinical Devel.) | Sale | 60,668 | 23.25 | 1,410,531 |
| 2011-03-16 | Hara Izumi (Sr. VP, Gen. Counsel & Sec.) | Sale | 63,531 | 23.25 | 1,477,095 |
| 2011-03-16 | Herendeen Paul (Exec. V.P. and CFO) | Sale | 400,000 | 23.25 | 9,300,000 |
| 2011-03-16 | Reichel Carl W (President, Pharmaceuticals) | Sale | 400,000 | 23.25 | 9,300,000 |
| 2011-03-16 | Jpmp Capital Corp (10% Owner) | Sale | 15,722,194 | 22.44 | 352,743,144 |
| 2011-03-16 | Abbrecht Todd M | Sale | 7,861,448 | 23.25 | 182,778,666 |
| 2011-03-16 | Connaughton John (Director) | Sale | 6,919,748 | 22.44 | 155,251,466 |
| 2011-03-16 | Murray Stephen (Director) | Sale | 7,861,447 | 22.44 | 176,379,424 |
| 2011-01-31 | Fuhrmann Rochelle (Senior V.P., Global Finance) | Sale | 834 | 23.35 | 19,473 |
| 2011-01-31 | Gilligan Claire A (Senior V.P. Global Quality) | Sale | 1,422 | 23.35 | 33,201 |
| 2011-01-31 | Van Zoonen Marinus Johannes (Pres., Europe/Int'l&Glob. Mkt.) | Sale | 6,645 | 23.35 | 155,154 |
| 2011-01-31 | Boissonneault Roger M (CEO & President) | Sale | 24,684 | 23.35 | 576,345 |
| 2011-01-31 | Bruno Anthony D (Exec. V.P., Corp. Development) | Sale | 6,456 | 23.35 | 150,741 |
| 2011-01-31 | Cross Leland H (Senior V.P., Tech. Operations) | Sale | 1,716 | 23.35 | 40,065 |
| 2011-01-31 | Ellman Herman (Senior V.P., Clinical Devel.) | Sale | 1,716 | 23.35 | 40,065 |
| 2011-01-31 | Herendeen Paul (Exec. V.P. and CFO) | Sale | 6,456 | 23.35 | 150,741 |
| 2011-01-31 | Howard Alvin D (Sr. V.P., Regulatory Affairs) | Sale | 1,716 | 23.35 | 40,065 |
| 2011-01-31 | Reichel Carl W (President, Pharmaceuticals) | Sale | 6,456 | 23.35 | 150,741 |
| 2011-01-21 | Fuhrmann Rochelle (Senior V.P., Global Finance) | Sale | 485 | 23.62 | 11,456 |
| 2011-01-21 | Gilligan Claire A (Senior V.P. Global Quality) | Sale | 929 | 23.62 | 21,944 |
| 2011-01-21 | Boissonneault Roger M (CEO & President) | Sale | 13,580 | 23.62 | 320,786 |
| 2011-01-21 | Bruno Anthony D (Exec. V.P., Corp. Development) | Sale | 4,097 | 23.62 | 96,779 |
| 2011-01-21 | Cross Leland H (Senior V.P., Tech. Operations) | Sale | 1,054 | 23.62 | 24,897 |
| 2011-01-21 | Ellman Herman (Senior V.P., Clinical Devel.) | Sale | 1,164 | 23.62 | 27,496 |
| 2011-01-21 | Herendeen Paul (Exec. V.P. and CFO) | Sale | 4,096 | 23.62 | 96,755 |
| 2011-01-21 | Howard Alvin D (Sr. V.P., Regulatory Affairs) | Sale | 1,219 | 23.62 | 28,795 |
| 2011-01-21 | Reichel Carl W (President, Pharmaceuticals) | Sale | 4,096 | 23.62 | 96,755 |
| 2011-01-11 | Gilligan Claire A (Senior V.P. Global Quality) | Sale | 829 | 23.85 | 19,771 |
| 2011-01-11 | Cross Leland H (Senior V.P., Tech. Operations) | Sale | 1,030 | 23.85 | 24,565 |
| 2011-01-11 | Ellman Herman (Senior V.P., Clinical Devel.) | Sale | 1,030 | 23.85 | 24,565 |
| 2011-01-11 | Howard Alvin D (Sr. V.P., Regulatory Affairs) | Sale | 1,133 | 23.85 | 27,022 |
| 2010-10-21 | Fawzi Mahdi B (President, Research & Develop.) | Sale | 2,467 | 24.20 | 59,701 |
| 2010-09-30 | Credit Suisse Ag/ | Sale | 15,000,000 | 21.48 | 322,200,000 |
| 2010-09-29 | Credit Suisse Ag/ | Sale | 322,797 | 22.50 | 7,263,255 |
| 2010-09-28 | Credit Suisse Ag/ | Sale | 575,000 | 22.53 | 12,955,325 |
| 2010-09-27 | Alpinvest Partners Later Stage Co-investments Custodian Ii B.v. (Other) | Sale | 651,028 | 22.68 | 14,765,315 |
| 2010-09-24 | Alpinvest Partners Later Stage Co-investments Custodian Ii B.v. (Other) | Sale | 1,649,645 | 22.78 | 37,578,913 |
| 2010-09-23 | Alpinvest Partners Later Stage Co-investments Custodian Ii B.v. (Other) | Sale | 393,237 | 22.85 | 8,985,465 |
| 2010-09-22 | Gilligan Claire A (Senior V.P. Global Quality) | Sale | 956 | 23.05 | 22,033 |
| 2010-09-22 | Alpinvest Partners Later Stage Co-investments Custodian Ii B.v. (Other) | Sale | 481,240 | 22.92 | 11,030,020 |
| 2010-09-22 | Cross Leland H (Senior V.P., Tech. Operations) | Sale | 1,171 | 23.05 | 26,989 |
| 2010-09-22 | Ellman Herman (Senior V.P., Clinical Devel.) | Sale | 1,171 | 23.05 | 26,989 |
| 2010-09-22 | Howard Alvin D (Sr. V.P., Regulatory Affairs) | Sale | 1,422 | 23.05 | 32,774 |
| 2010-09-14 | Credit Suisse Ag/ | Sale | 124,717 | 22.01 | 2,745,395 |
| 2010-09-13 | Credit Suisse Ag/ | Sale | 38,712 | 22.05 | 853,677 |
| 2010-09-10 | Credit Suisse Ag/ | Sale | 109,800 | 22.03 | 2,419,113 |
| 2010-08-13 | Bloem James H (Director) | Option Ex | 19,176 | 16.73 | 320,756 |
Insider trading activities including stock purchases, stock sales, and option exercises
of WCRX listed in the above tables cannot be completely guaranteed as to their accuracy.
For more insider trading information of Warner Chilcott Ltd (symbol WCRX,
CIK number 1323854) see
the Securities and Exchange Commission (SEC) website.